We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
+8.39%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$200M
AUM Growth
-$24.6M
(-11%)
Cap. Flow
-$17.4M
Cap. Flow
% of AUM
-8.71%
Top 10 Holdings %
Top 10 Hldgs %
93.52%
Holding
34
New
3
Increased
4
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Milestone Pharmaceuticals
MIST
|
+$3.26M |
| 2 |
Semtech
SMTC
|
+$2.32M |
| 3 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$1.15M |
| 4 |
NFYS
Enphys Acquisition Corp.
NFYS
|
+$827K |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$215K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DRRX
DURECT Corp
DRRX
|
+$1.06M |
| 2 |
Battalion Oil
BATL
|
+$1M |
| 3 |
Seres Therapeutics
MCRB
|
+$461K |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$409K |
| 5 |
Ardelyx
ARDX
|
+$112K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.28% |
| 2 | Healthcare | 13.08% |
| 3 | Consumer Discretionary | 1.18% |
| 4 | Energy | 1.07% |
| 5 | Financials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Aclaris Therapeutics
ACRS
$726M
| $122K | 0.06% |
115,898
| – | – |
|
|
BFIIW
27
DELISTED
BurgerFi International, Inc. Warrant
BFIIW
| $93.8K | 0.05% |
+2,083,438
| New | +$138K |
|
28
Microsoft
MSFT
$3.45T
| $37.6K | 0.02% |
100
| – | – |
|
29
Alphabet (Google) Class C
GOOG
$4.36T
| $14.1K | 0.01% |
100
| – | – |
|
30
Chevron
CVX
$392B
| – | – |
-46
| Closed | -$7.76K |
|
|
DRRX
31
DELISTED
DURECT Corp
DRRX
| – | – |
-427,455
| Closed | -$1.06M |
|
32
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| – | – |
-50,000
| Closed | -$21.4M |
|
|
BFIIW
33
CALL
DELISTED
BurgerFi International, Inc. Warrant
BFIIW
| – | – |
-2,083,438
| Closed | -$235K |
|
Similar funds
PA
SR
SCTC
SRA
CP
B
BCPE
AE
Lion Point Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Lion Point Capital held 34 positions worth $200M, down 11% from $224M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Lion Point Capital withdrew a net $17.4M in Q4 2023, closing 4 positions and reducing 5 holdings. Its most notable exit was DURECT Corp, an estimated $1.06M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Lion Point Capital opened a new position in Enphys Acquisition Corp. worth $834K.
- Lion Point Capital's largest Q4 2023 buy was Enphys Acquisition Corp.: 78,125 shares worth $834K.
- Lion Point Capital added most to Milestone Pharmaceuticals in Q4 2023, an estimated $3.26M increase.
- Lion Point Capital's biggest Q4 2023 reduction was Battalion Oil, cutting an estimated $1M.
- Lion Point Capital fully exited DURECT Corp in Q4 2023, selling an estimated $1.06M.
- Lion Point Capital's ten largest holdings make up 94% of its $200M portfolio in Q4 2023.
- Lion Point Capital opened 3 new positions and closed 4 in Q4 2023.
- Lion Point Capital's portfolio value fell 11% quarter-over-quarter to $200M.
Based on Lion Point Capital's 13F filing for Q4 2023, filed 14 Feb 2024.